Growth in buprenorphine waivers for physicians increased potential access to opioid agonist treatment, 2002-11

Health Affairs

Volumn 34, Issue 6, 2015, Pages 1028-1034

  Dick, Andrew W ^a   Pacula, Rosalie L ^a   Gordon, Adam J ^b,c   Sorbero, Mark ^d   Burns, Rachel M ^d   Leslie, Douglas ^e   Stein, Bradley D ^b,d  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d RAND Pittsburgh   (United States)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CONTROLLED SUBSTANCE; METHADONE; NARCOTIC ANALGESIC AGENT;

ARTICLE; CERTIFICATION; CLINICAL PRACTICE; DRUG CONTROL; DRUG MISUSE; FOOD AND DRUG ADMINISTRATION; GEOGRAPHIC DISTRIBUTION; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; OPIATE ADDICTION; PHYSICIAN; PRESCRIPTION; PUBLIC HEALTH PROBLEM; RURAL AREA; UNITED STATES; URBAN POPULATION; URBAN RURAL DIFFERENCE; LEGISLATION AND JURISPRUDENCE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; RURAL POPULATION; STATISTICS AND NUMERICAL DATA;

ANALGESICS, OPIOID; BUPRENORPHINE; CONTROLLED SUBSTANCES; DRUG AND NARCOTIC CONTROL; DRUG PRESCRIPTIONS; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PHYSICIANS; RURAL POPULATION; UNITED STATES;

EID: 84930916012     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.1205     Document Type: Article

References (59)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington (DC): APA; 2013.
2. Center for Behavioral Health Statistics and Quality. Trends in the use of methadone and buprenorphine at substance abuse treatment facilities: 2003 to 2011 [Internet]. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2003 Apr 23 [cited 2015 Mar 26]. Available from: http://www.samhsa.gov/data/sites/default/files/NSSATS%20Rprt%20Trnds%20Use%20Methadone%20&%20Buprenorphine%20at%20SA%20Trmt%20Facs%20%2003-11/NSSATS%20Rprt%20Trnds%20Use%20Methadone%20&%20Buprenorphine%20at%20SA%20Trmt%20Facs%20%2003-11/sr107-NSSATS-Buprenorph.pdf
3. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse, and dependence on prescription opioids among U.S. adults: psychiatric, medical, and substance use correlates. Drug Alcohol Depend. 2008;94(1-3):38-47.
4. Becker WC, Fiellin DA, Desai RA. Non-medical use, abuse, and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend. 2007;90(2-3):280-7.
5. Johnson KM, Fibbi M, Langer D, Silva K, Lankenau SE. Prescription drug misuse and risk behaviors among young injection drug users. J Psychoactive Drugs. 2013;45(2):112-121.
6. Paulozzi LJ. Prescription drug overdoses: a review. J Safety Res. 2012; 43(4):283-9.
7. Birnbaum HG,White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657-67.
8. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000; 284(13):1689-95.
9. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009 (3):CD002209.
10. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008 (2):CD002207.
11. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349(10):949-58.
12. American Methadone Treatment Association. 1998 methadone maintenance program and patient census in the US. New York (NY): American Methadone Treatment Association; 1999.
13. O'Brien CP. A 50-year-old woman addicted to heroin: review of treatment of heroin addiction. JAMA. 2008;300(3):314-21.
14. Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011; 30(8):1425-33.
15. Center for Substance Abuse Treatment. The determinations report: a report on the physician waiver program established by the Drug Addiction Treatment Act of 2000 ("DATA") [Internet]. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2006 Mar 30 [cited 2015 Mar 16]. Available from: http://buprenorphine.samhsa.gov/SAMHSA_Determinations_Report.pdf
16. Ducharme LJ, Abraham AJ. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy. 2008;3:17.
17. Fiellin DA, O'Connor PG. Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med. 2002;347(11):817-23.
18. Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374-81.
19. Cunningham CO, Kunins HV, Roose RJ, Elam RT, Sohler NL. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med. 2007;22(9):1325- 29.
20. Stein BD, Gordon AJ, Dick AW, Burns RM, Pacula RL, Farmer CM, et al. Supply of buprenorphine waivered physicians: the influence of state policies. J Subst Abuse Treat. 2015;48(1):104-11.
21. Health Resources and Services Administration. HPSA designation criteria [Internet]. Rockville (MD): HRSA; [cited 2015 Mar 17]. Available from: http://bhpr.hrsa.gov/shortage/hpsas/designationcriteria/designationcriteria.html
22. Warner M, Chen LH, Makuc DM, Anderson RN, Miniño AM. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief. 2011(81):1-8.
23. To access the Appendix, click on the Appendix link in the box to the right of the article online.
24. Department of Agriculture Economic Research Service. Rural-Urban Continuum Codes: overview [Internet]. Washington (DC): USDA; [last updated 2013 May 10; cited 2015 Apr 1]. Available from: http://www.ers.usda.gov/data-products/rural-urban-continuum-codes.aspx
25. Gordon AJ, Liberto J, Granda S, Salmon-Cox S, Andree T, McNicholas L. Outcomes of DATA 2000 certification trainings for the provision of buprenorphine treatment in the Veterans Health Administration. Am J Addict. 2008; 17(6):459-62.
26. Gordon AJ, Trafton JA, Saxon AJ, Gifford AL, Goodman F, Calabrese VS, et al. Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years. Drug Alcohol Depend. 2007;90(2-3):292-6.
27. Stein BD, Burns RM, Pacula RL, Dick AW, Bauhoff S, Sorbero M, et al. Where is buprenorphine dispensed? The role of private offices, OTP's, and substance abuse treatment facilities in urban and rural areas. Unpublished paper.
28. Stein BD, Dick AW, Sorbero M, Burns RM, Pacula RL, Gordon AJ, et al. Patterns of buprenorphine use among Medicaid-enrolled individuals with opioid use disorders. Paper presented at: 2014 Addiction Health Services Research Conference; 2014 Oct 15; Boston (MA).
29. Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers-United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013;132(1-2):95-100.
30. Oliva EM, Trafton JA, Harris AH, Gordon AJ. Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse. 2013;39(2):103-7.
31. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: summary of national findings [Internet]. Rockville (MD): SAMHSA; 2013 Sep [cited 2015 Mar 17]. Available from: http://www.samhsa.gov/data/sites/default/files/NSDUHnationalfindingresults2012/NSDUHnationalfindingresults2012/NSDUHresults2012.pdf
32. Ku L, Jones K, Shin P, Bruen B, Hayes K. The states' next challenge-securing primary care for expanded Medicaid populations. N Engl J Med. 2011;364(6):493-5.
33. Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23-6.
34. Roman PM, Abraham AJ, Knudsen HK. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav. 2011;36(6):584-9.
35. Burns RM, Pacula RL, Bauhoff S, Gordon AJ, Hendrikson H, Leslie DL, et al. Policies supporting opioid agonist therapy of opioid use disorders: the evolution of state policies from 2004 to 2013. Unpublished paper.
36. Barry CL, Huskamp HA. Moving beyond parity-mental health and addiction care under the ACA.N Engl J Med. 2011;365(11):973-5.
37. Levit KR, Mark TL, Coffey RM, Frankel S, Santora P, Vandivort-Warren R, et al. Federal spending on behavioral health accelerated during recession as individuals lost employer insurance. Health Aff (Millwood). 2013;32(5):952-62.
38. Levit KR, Stranges E, Coffey RM, Kassed C, Mark TL, Buck JA, et al. Current and future funding sources for specialty mental health and substance abuse treatment providers. Psychiatr Serv. 2013;64(6):512-9.
39. Becker WC, Fiellin DA, Merrill JO, Schulman B, Finkelstein R, Olsen Y, et al. Opioid use disorder in the United States: Insurance status and treatment access. Drug Alcohol Depend. 2008;94(1-3):207-13.
40. Bauhoff S, Stein BD, Pacula RL, Dick AW, Gordon AJ, Burns RM, et al. Do substance abuse policies influence opioid agonist therapies in substance abuse treatment facilities? Paper presented at: 2014 Addiction Health Services Research Conference; 2014 Oct 15; Boston (MA).
41. Busch SH, Epstein AJ, Harhay MO, Fiellin DA, Un H, Leader D Jr, et al. The effects of federal parity on substance use disorder treatment. Am J Manag Care. 2014;20(1):76-82.
42. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96(9):1267-78.
43. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1-171, iii-iv.
44. Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003; 71(3):295-302.
45. Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer C. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend. 2012;123(1-3): 72-8.
46. Substance Abuse and Mental Health Services Administration. Buprenorphine training events [Internet]. Rockville (MD): SAMHSA; [cited 2015 Mar 17]. Available from: http://buprenorphine.samhsa.gov/training_main.html
47. American Osteopathic Academy of Addiction Medicine. PCSS-MAT self study [Internet]. Oak Brook (IL): AOAAM; [cited 2015 Mar 17]. Available from: http://www.aoaam.org/content.php?pg=2
48. American Academy of Addiction Psychiatry. Buprenorphine waiver training [Internet]. East Providence (RI): AAAP; [cited 2015 Mar 17]. Available from: http://www.aaap.org/education-training/buprenorphine/
49. Egan JE, Casadonte P, Gartenmann T, Martin J, McCance-Katz EF, Netherland J, et al. The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med. 2010;25(9):936-41.
50. Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O'Connor PG, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007; 22(4):527-30.
51. Walley AY, Alperen JK, Cheng DM, Botticelli M, Castro-Donlan C, Samet JH, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008; 23(9):1393-8.
52. Substance Abuse and Mental Health Services Administration. Buprenorphine: physician waiver qualifications [Internet]. Rockville (MD); SAMHSA; [cited 2015 Mar 17]. Available from: http://buprenorphine.samhsa.gov/waiver_qualifications.html
53. Link BG, Struening EL, Rahav M, Phelan JC, Nuttbrock L. On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. J Health Soc Behav. 1997;38(2):177-90.
54. Luoma JB, Twohig MP, Waltz T, Hayes SC, Roget N, Padilla M, et al. An investigation of stigma in individuals receiving treatment for substance abuse. Addict Behav. 2007; 32(7):1331-46.
55. Kissin W, McLeod C, Sonnefeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006; 25(4):91-103.
56. Galanter M, Keller DS, Dermatis H, Egelko S. The impact of managed care on substance abuse treatment: a report of the American Society of Addiction Medicine. J Addict Dis. 2000;19(3):13-34.
57. D'Aunno T. The role of organization and management in substance abuse treatment: review and roadmap. J Subst Abuse Treat. 2006;31(3):221-233.
58. Hutchinson E, Catlin M, Andrilla CH, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128-133.
59. Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011; 5(1):21-27.